Thu, Apr 24, 2014, 11:18 AM EDT - U.S. Markets close in 4 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • zwerp2000 zwerp2000 Jan 4, 2013 6:56 AM Flag

    Novapharm is clueless

    And someone you should never listen to.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And you are so full of clues - upgrade to $30, mention in AF article - that's all in the past, this is OVER. In the near future - dilution in order to raise $$ for launch and no more upgrades.

      I'll give you another clue - the ANALysts were tripping all over to upgrade in order for the institutions to dump their shares on you and to get a piece of underwriting fees from the coming capital raise.

      And even if ISIS gets a CRL the stock won't go up because it would not affect the clue above.

      And since you started this thread without quoting, I'll have to quote to fill in the void

      Novapharma:
      Shorting another 5K shares of Aegerion $AEGR at $28.04 as they need $ and $ISIS is up for approval this month w/ a competing HOFH treatment.

      Didn't think I'd get the opp. to short Aegerion $AEGR again so soon! $27.45 - Shorting it heavily now. $ISIS will take 50% of it's market.

      Sentiment: Strong Sell

      • 1 Reply to vd6rt
      • Novapharm is an idiot. ISIS was denied by the EMEA and will probably be denied by the FDA too. Even if the FDA grants approval for ISIS, AEGR will have the drug of choice. Moreover, AEGR will receive EMEA approval and own the European market. AEGR is undervalued. The stock has a lot of momentum. ISIS is fumbling around. Just yesterday a few law firms are looking to sue the company. Wow. ISIS is crumbling and so is novapharm

    • when isis gets denied aegr jumps to mid 30s

 
AEGR
45.84+1.92(+4.37%)11:18 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.